Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmaceutical Costs topic
No spam. Unsubscribe anytime.
HCAI brief: GLP‑1 prescriptions in California rose from ~20,000 to over 700,000 (2018–2023); committee flags monitoring needs
Summary
HCAI staff reported a rapid increase in GLP‑1 prescriptions (2018–2023) and estimated 2023 statewide GLP‑1 spending of about $822 million across Medi‑Cal and commercial plans; advisory members urged continued study of utilization, clinical benefit, and long‑term cost impacts.
HCAI presented a Health Care Payments Database analysis showing a dramatic rise in GLP‑1 prescriptions for weight loss in California. "GLP-one utilization, from 2018 to 2023 increased substantially for weight loss utilization in the state of California from 20,000 prescriptions to over 700,000 prescriptions," Vishal Pagani told the committee, noting statewide 2023 GLP‑1 spending was roughly $822 million for Medi‑Cal and commercial plans and an average per‑member annual cost of about $5,329 for those receiving prescriptions.
Advisory members probed how HCAI will continue monitoring utilization and its downstream effects on health system costs, including whether drug costs are offset by reduced downstream spending. Committee members and public commenters urged HCAI to disaggregate usage by subpopulations, examine long‑term outcomes and return‑on‑investment by cohort, and consider how reimbursement and direct‑to‑consumer channels may change trends.
HCAI staff committed to tracking GLP‑1 trends and comparing Medi‑Cal versus commercial patterns as coverage changes evolve. The committee emphasized the importance of clarifying which price measures are being used (e.g., list price vs. net after rebates) and recommended further ROI and subgroup analyses before drawing policy conclusions.
